HPV预防性疫苗高效力原因解析
HPV L1病毒样颗粒(VLP)疫苗按三剂次程序接种已显示显著预防效力,单剂次接种也显示相似效力与效果。单剂VLP疫苗的高效力可能主要归因于颗粒结构特征及病毒生命周期特点。
要点
- 三剂次VLP疫苗在临床试验和免疫规划中显示高效力。
- 单剂次接种也显示相似效力与效果。
- 单剂高效力可能与VLP结构及病毒生命周期有关。
核心结论
- 单剂VLP疫苗的高效力可能主要归因于颗粒结构特征及病毒生命周期特点。
研究设计与样本
- 原文未报告
主要发现
- 三剂次VLP疫苗在临床试验中显示显著预防效力,在免疫规划中显示效果。
- 有不断增加证据表明单剂次接种也显示相似效力与效果。
- 单剂VLP疫苗的高效力可能归因于颗粒结构特征及病毒生命周期特点。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
HPV L1 virus-like particle (VLP) vaccines administered in a prime/boost series of three injections over six months have demonstrated remarkable prophylactic efficacy in clinical trials and effectiveness in national immunization programs with high rates of coverage. There is mounting evidence that the vaccines have similar efficacy and effectiveness even when administered in a single dose. The unexpected potency of one dose of these VLP vaccines may largely be attributed to structural features of the particles, which lead to the efficient generation of long-lived antigen-specific antibody-producing cells and unique features of the virus life cycle that make the HPV virions highly susceptible to antibody-mediated inhibition of infection.
引用
- Schiller J, Lowy D. Explanations for the high potency of HPV prophylactic vaccines. Vaccine. 2018. PMID: 29325819. doi:10.1016/j.vaccine.2017.12.079
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。